See the latest news and media coverage for Xintela. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing stem cell and targeted cancer therapies
xintela.seLast updated
In short: Xintela improved financial results, secured patents in the US and Japan, and reported positive clinical data for its XSTEM product.
Revenue rose to 1.3 MSEK in the second quarter while operating profit improved. The company secured a convertible loan and received new patent grants for XSTEM® in the US and Japan.
The results show reduced knee pain, improved joint function as well as improved cartilage and bone tissue, supporting a disease-modifying effect.
The loan from main owner Flerie Invest will accelerate XSTEM development and repay previous loan.
No serious adverse events were reported, and the company plans to evaluate XSTEM on other wound indications.
Xintela, which develops medical products within stem cell therapy and targeted cancer therapy, reports a pre-tax result of -9.8 million kronor...
Xintela (XINT) announces today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of the company's stem cell...
Find the latest Xintela AB (publ) (XINT.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.
Visit a quote page and your recently viewed tickers will be displayed here.
Track Xintela and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Xintela and other trending companies.